Myotis Bat Genome Longevity Cancer Study
Analysis based on 11 articles · First reported Aug 26, 2026 · Last updated Sep 12, 2026
The study is early-stage basic science with no immediate commercial product, so direct market impact is limited, though it may modestly support sentiment for longevity and oncology-focused biotechnology research. Over time, insights into DNA-damage response and immune gene copy-number variation could inform drug discovery pipelines in aging and cancer therapeutics.
An international research team led by the University of Vermont and Pennsylvania State University published a study in Nature on August 26, 2026, presenting the first near-complete genome assemblies and cell lines for eight Myotis bat species. The work, co-led by Elise Lauterbur and Juan Manuel Vázquez, found that pathogen adaptation, longevity, and cancer resistance are genetically linked in bats. Long-lived bats showed positive selection in pathways related to longevity and cancer, and distinctive adaptation patterns to DNA versus RNA viruses compared with humans and other primates. The little brown bat, Myotis lucifugus, responded to severe DNA damage by increasing programmed cell death rather than DNA repair, a strategy also seen in elephants. Researchers also found that some Myotis species carry two or three copies of the immune gene PKR (EIF2AK2), with duplicated copies contributing to antiviral activity but also greater cellular toxicity. The study was funded by the United States — National Institutes of Health and the United States — National Science Foundation, with co-authors from the University of California, Berkeley, the University of Chicago, the University of Arizona, and the Ecole normale superieure de Lyon. The findings do not provide a treatment for cancer or a method for extending human lifespan, but offer a natural model for studying how immunity, cellular damage, and aging are connected.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard